



G1 Therapeutics to Participate in BTIG and Webbush Healthcare Conferences in August

August 6, 2019

RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that the company will participate in two investor conferences in August 2019.

- The company will meet with investors at the 2019 BTIG Biotechnology Conference on Monday, August 12 at the St. Regis New York in New York, NY.
- Chief Executive Officer Mark Velleca, M.D., Ph.D. will present a company overview at the 2019 Webbush PacGrow Healthcare Conference on Tuesday, August 13 at 8:35 a.m. ET at the Parker New York in New York, NY.

To access the live webcast of the Webbush PacGrow Healthcare Conference, please visit the [Events & Presentations page](#) within the Investors section of the [G1 website](#). The webcast will be archived on the same page for 90 days following the event.

About G1 Therapeutics

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs. [Trilaciclib](#) is a first-in-class myelopreservation agent designed to improve outcomes for patients being treated with chemotherapy. [Lerociclib](#) is a differentiated oral CDK4/6 inhibitor designed to enable more effective combination treatment strategies. [G1T48](#) is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. G1 also has an active discovery program focused on cyclin-dependent kinase targets.

G1 is based in Research Triangle Park, NC. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Contact:

Jeff Macdonald
Head of Investor Relations / Public Relations
919-907-1944
jmacdonald@g1therapeutics.com



Source: G1 Therapeutics